Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population
A phase 3 study of Gilead’s Livdelzi has met its primary endpoint,
TL;DRAI
Livdelzi met phase 3 primary endpoint in PBC, expanding use to UDCA-intolerant patients showing normalized alkaline phosphatase levels. $133M Q1 2026 sales (3.3× YoY) validates Gilead's $4.3B CymaBay acquisition and market position vs Iqirvo in rare hepatic disease.
507 words~2 min read
